Super Early Bird Ends Tomorrow – Accelerate Your Fundraising Efforts at Digital RESI March 2022

27 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireWe just wrapped another successful Redefining Early Stage Investments (RESI) Conference, and now we are busily preparing for our next event: Digital RESI March 22-24.

Digital RESI March will bring together over 300 investor attendees who are interested in meeting startup companies for potential investment, strategic partnership, and more. In addition to all day partnering across the three-day conference, Digital RESI will feature an engaging program of investor panels, workshops, and Innovator’s Pitch Challenge (IPC) sessions. Super Early Bird rates are ending tomorrow, Friday, January 28th. Don’t miss out on the opportunity to save $300 on your registration!

resi-march-2022

Sponsorship at RESI: Getting your message to your target audience

27 Jan

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

As we enter year three of the Covid-19 pandemic, companies and organizations need to be creative about ways to get their message out and gain visibility. The days of attending networking events and making contacts in unplanned meetings are still on the horizon. In the absence of these ad hoc meetings, how do you reach your target audience?  How do you showcase your expertise to potential customers in the digital/virtual world we live in today?

Organizations that want to reach early-stage, life science startups can get great visibility at the Digital RESI March conference. Sponsors at RESI March have a myriad of opportunities to reach their target audience, such as hosting a live workshop at the event. At our last RESI conference, Digital RESI JPM, sponsors held live workshops on topics that really matter to start-ups, such as

  • Negotiating Term Sheets
  • Licensing in the Life Sciences
  • Evaluating your Banking Partner
  • Fundraising Challenges for First-time Entrepreneurs

Sessions like these put a spotlight on the expertise that sponsors have in certain areas and offer the chance to make connections with companies needing these services. In addition, the Service Provider Showcase on the RESI Live Agenda is great for brand recognition.

Let us know if you would like to discuss sponsorship opportunities at RESI. Contact Us!

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International East Coast (USA) & China Midwest (USA)
& Canada		 West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development, General Manager Europe
Book a Meeting		 Candice He
Vice President of Business Development, Global Investment Strategist
Book a Meeting		 Antoinette Lowre
Manager of Business Development
Book a Meeting		 Alexander Vassallo
Manager of Business Development
Book a Meeting

resi-march-2022

Pre-RESI Bootcamps – Preparing for the Innovator’s Pitch Challenge

27 Jan

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

At our recent RESI JPM conference, 55 selected life science startups pitched in 11 live Q&A sessions to relevant investor judges, in the Innovator’s Pitch Challenge. The IPC continues to be the most popular feature of the RESI conferences. Presenters benefited from showcasing their technology to both the investors on the judging panel and the audience. Additionally, many investor attendees said the unique format of IPC is an efficient way to learn about a company.

As the IPC is getting more traction, the Life Science Nation team will be hosting two FREE Pre-RESI Bootcamps on Preparing for the Innovator’s Pitch Challenge. The bootcamp will explain the timeline, format, and frequently asked questions from the investor panel, to help the interested companies to get a better understanding of what to expect and how to prepare to pitch at RESI.

Pre-RESI Bootcamps: Preparing for the Innovator’s Pitch Challenge
1 Wednesday, February 2nd at 12PM EST Register Here
2 Wednesday, February 23rd at 2PM EST Register Here

The pitch slots are limited, and we accept applications on a first-come, first-served basis, so we encourage you to fill out the free 5-min application at your earliest convenience.

apply-ipc

*A one-day or three-day registration + $800 pitch fee are required to participate.

resi-march-2022

Hot Investor Mandate: USA-Based PE Firm Invests Up to $30M, With Broad Interests in Healthcare, Including Laboratory Equipment and R&D Services

27 Jan

A Private Equity firm that was founded in 2011 with offices in USA. The firm is currently making investments out of its vintage 2020 fund. The firm looks to make primarily growth equity investments ranging from $5-$30 million with most investments falling in the $10-$30 million range. The firm is willing to review opportunities from around the Globe.

The firm is currently interested broadly in the healthcare space including Medical Technology, Therapeutics, Diagnostics, Laboratory Equipment, Healthcare IT and R&D services. For medical technology the firm is looking for companies that have at least an alpha prototype and have some efficacy data.  For companies working with therapeutics the firm is looking for assets that are in Phase II of clinical trials and will only consider companies in Phase I if they have efficacy data. The firm generally does not look for companies in the cardiovascular space and they are open to orphan indications. The firm is also open to investing in companies that have products already on the market.

The firm looks for a strong management team to be in place and is open to invest in both private and publicly held companies. For companies that are privately held the firm generally looks to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Taiwan-Based Evergreen Fund Invests in Novel Therapeutics, Medical Devices, and Digital Health Companies Across the Globe

27 Jan

A firm based in Taiwan invests from an evergreen fund, and is a multi-stage investor, with investments made from seed stage all the way to IPO. The firm invests both in Taiwan and internationally, including in the US and Canada.  Investments are typically of $500,000-2 million.

The firm invests in a variety of sectors including medical devices, therapeutics, and digital health/AI.  The firm prefers to invest in companies with a pipeline of multiple assets rather than in single asset companies.  For therapeutics, the firm looks internationally for novel assets: within Taiwan, the firm focuses on repurposed drugs.

The firm prefers to invest in companies that already have a complete team.  For medical device companies, this must include commercial/sales staff.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Leading Investment Firm in USA Invests $10-30M in Both Public and Privately Owned Life Science Companies in North America and Europe

27 Jan

A leading healthcare venture capital firm with multiple offices in USA invests in transformative biotechnology, medical technology, and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. The firm invests in both privately held and publicly traded companies through a variety of investment approaches.

The firm has raised nearly $2 billion in capital commitments and is investing from a fourth core fund of $585 million. The firm makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. The firm primarily invests in North America and Europe but may also consider opportunities in the Middle East.

The firm invests in biotechnology, medical technology, diagnostics, healthcare services, and healthcare IT. The firm is generally agnostic regarding indications. The firm invests across a range of stages, from development through profitability, but prefers to back technologies that have attained proof of concept data.

The firm invests in both pre-revenue companies and post-revenue companies. The firm typically leads or co-leads investments, and prefers to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Single Family Office Interested in Global Therapeutics, Diagnostics, and Digital Health Companies, With Strong Interests in Oncology and CNS Therapeutics

27 Jan

A single family office based in the USA actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries.

The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more.

The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →